CD8A and liver cancer: Pharmacologic FAK inhibition demonstrated efficacy against primary liver cancer (PLC) tumors in both orthotopic and subcutaneous mouse models and was associated with progressive reduction in fibrosis and angiogenesis and stimulation of cytotoxic CD8<sup>+</sup> T cell function.